Lobbyist Public Search

Records prior to registration year 2005 are not available online. Contact the Lobbyist Division here for assistance.	Search data is collected from registration records and disclosure reports submitted by lobbyists, lobbying entities, and their clients. Massachusetts General Law requires any party providing or retaining lobbying services to register annually, and submit disclosure reports twice a year.
	Your comments are welcome: submit feedback

Disclosure reporting details

Back to search detail summary

Lobbyist disclosure reporting period: 07/01/2020 - 12/31/2020

Lobbyist name	Geoffrey A Gallo
Business name	AstraZeneca Pharmaceuticals, LP
Address	3 Merles Lane
City, state, zip code	Stratham, NH 03885
Country	USA
Agent type	Both
Phone	603-770-9000

Operating Expenses

Date	Recipient	Type of expense	Amount
12/31/2020	US Postal Service	Postage, shipping, delivery	$30.00
12/31/2020	Verizon Wireless	Telephone, cell phone, handheld	$513.00
		Total operating expenses	$543.00

Activities, Bill Numbers and Titles

Client: AstraZeneca Pharmaceuticals LP

Total amount paid by client; lobbyist is unable to report compensation at activity level: $14,500.00

House / Senate	Bill Number or Agency Name	Bill title or activity	Agent position	Amount	Direct business association
Executive	Other	Engaged in discussions with members of the Executive and Legislative branches concerning the development of AstraZeneca’s COVID-19 vaccine. Specifically members of the House COVID-19 Working Group. These topics pertained to the progress of clinical trials, distribution, and supply.	Neutral	$0.00	N/A
House Bill	1099	An Act to help patients and reduce health care costs by ensuring patient adherence to medications	Support	$0.00	N/A
House Bill	629	An Act relative to pharmaceutical pricing	Oppose	$0.00	N/A
Senate Bill	717	An Act to create a special commission to improve transparency and affordability at the Group Insurance Commission	Oppose	$0.00	N/A
House Bill	1933	An Act to improve patient access to cancer clinical trial programs	Neutral	$0.00	N/A
Executive	Massachusetts Health Policy Commission (HPC)	Promoted and assisted with information pertaining to the HPC study on the use of prescription drug coupons and vouchers.	Support	$0.00	N/A
House Bill	916	An Act relative to co-pay assistance	Support	$0.00	N/A
Senate Bill	2397	An Act relative to pharmaceutical access, costs and transparency (Amendments 2, 14, 29, 29, 30, 32, 34, 38, 39, 40, 41,42 and 44)	Oppose	$0.00	N/A
Senate Bill	696	An Act to promote transparency and cost control of pharmaceutical drug prices	Oppose	$0.00	N/A
House Bill	1013	An Act relative to pharmaceutical gag clauses	Neutral	$0.00	N/A
House Bill	3800	An Act making appropriations for the fiscal year 2020 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements (Amendment #1057)	Support	$0.00	N/A
Senate Bill	1206	An Act to ensure the fair, transparent and patient-focused use of health technology assessments by the Commonwealth	Support	$0.00	N/A
House Bill	1972	An Act to permit the wholesale importation of prescription drugs into the Commonwealth	Oppose	$0.00	N/A
House Bill	5164	An Act making appropriations for the fiscal year 2021 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements (Amendment #86 to FY21 Budget- Opioid Manufacturers Excise Tax; Amendment #’s 298 & 486 to FY21 Budget- Direct Negotiations for certain drugs & non-drug products.)	Neutral	$0.00	N/A
House Bill	898	An Act relative to consumer deductibles	Support	$0.00	N/A
House Bill	5164	An Act making appropriations for the fiscal year 2021 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements (Amendment #’s 268 & 488 to FY21 Budget- Penalty on Drug manufacturers for excessive price increases. )	Oppose	$0.00	N/A
Senate Bill	552	An Act to promote transparency in prescription drug prices	Oppose	$0.00	N/A
House Bill	931	An Act promoting high value and high quality care	Neutral	$0.00	N/A
Executive	Massachusetts Health Policy Commission (HPC)	Engaged in discussions related to the proposed rules for 101 CMR 801.00 and proposed drug pricing review regulations 958 CMR 12.00.	Neutral	$0.00	N/A
House Bill	1178	An Act relative to promoting transparency in the pharmaceutical industry	Support	$0.00	N/A
House Bill	1133	An Act to ensure prescription drug cost transparency and affordability	Oppose	$0.00	N/A
Senate Bill	1301	An Act to prevent undue influence on prescriber behavior	Oppose	$0.00	N/A
Senate Bill	652	An Act relative to pharmaceutical "gag clauses"	Neutral	$0.00	N/A
Executive	Massachusetts Health Policy Commission (HPC)	Interactions with the Health Policy Commission and participation in the HPC Advisory Council (virtually).	Support	$0.00	N/A
House Bill	926	An Act relative to consumer deductibles	Support	$0.00	N/A
Senate Bill	2397	An Act relative to pharmaceutical access, costs and transparency (Amendments 2, 14, 29, 29, 30, 32, 34, 38, 39, 40, 41,42 and 44)	Oppose	$0.00	N/A
Senate Bill	703	An Act to define modest meals and refreshments in prescriber education settings	Oppose	$0.00	N/A
House Bill	1168	An Act establishing a commission to review contracts between pharmaceutical benefit managers and MassHealth	Neutral	$0.00	N/A
Executive	Office of the Governor	Engaged on various COVID-19 Executive Orders to ensure compliance with our essential workers in MA. Specifically Executive Order# 53 pertaining to stay-at-home advisory, business capacities and early closures and capacities (order #54) and face coverings (Order #55).	Neutral	$0.00	N/A
House Bill	1178	An Act relative to promoting transparency in the pharmaceutical industry	Support	$0.00	N/A
House Bill	1177	An Act relative to protecting health care consumers	Oppose	$0.00	N/A
Senate Bill	721	An Act relative to mandatory prescription drug coverage	Oppose	$0.00	N/A
Senate Bill	652	An Act relative to pharmaceutical "gag clauses"	Neutral	$0.00	N/A
House Bill	4887	An Act enabling partnerships for growth (specifically supporting the section to extend the prescription drug co-pay assistance program.)	Support	$0.00	N/A
House Bill	3481	An Act to ensure the fair, transparent and patient-focused use of health technology assessments by the Commonwealth	Support	$0.00	N/A
House Bill	1162	An Act to promote transparency in prescription drug prices	Oppose	$0.00	N/A
Senate Bill	1701	An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing	Oppose	$0.00	N/A
Executive	Other	Discussions with the HPC and/or Advisory Council and CHIA with a focus on health care price variation, gross and net Rx drug costs to the state, as well as the establishment and implementation of Accountable Care Organizations (ACO’s). My interactions are with HPC Board Members, HPC Staff to include Executive Director, and the staff from the Center of Health Information Analysis (CHIA).	Neutral	$0.00	N/A
House Bill	3481	An Act to ensure the fair, transparent and patient-focused use of health technology assessments by the Commonwealth	Support	$0.00	N/A
House Bill	1154	An Act to reduce drug costs through transparency	Oppose	$0.00	N/A
Senate Bill	1352	An Act establishing a special commission to study and recommend improvements in the delivery of prescription drug benefits for the citizens of the Commonwealth	Oppose	$0.00	N/A
Executive	MassHealth	Participate in public meetings/discussions pertaining to drug costs (net and gross) and value-based contracts with health plans as well as MassHealth.	Support	$0.00	N/A
House Bill	949	An Act relative to non-medical switching	Support	$0.00	N/A
Senate Bill	2397	An Act relative to pharmaceutical access, costs and transparency (Amendments 2, 14, 29, 29, 30, 32, 34, 38, 39, 40, 41,42 and 44)	Oppose	$0.00	N/A
Senate Bill	706	An Act to ensure prescription drug cost transparency and affordability	Oppose	$0.00	N/A
House Bill	1177	An Act relative to protecting health care consumers	Neutral	$0.00	N/A
Executive	Massachusetts Health Policy Commission (HPC)	Engaged in the HPC Drug Pricing Review Process and the Standard Reporting Form. Specifically the process for determining valuation of Rx drugs, transparency requirements and rebate negotiations.	Oppose	$0.00	N/A
House Bill	915	An Act ensuring access to medications	Support	$0.00	N/A
Executive	Office of the Governor	Engaged in the opposition of the Governor’s Health Care Bill entitled An Act to Improve Health care by investing in VALUE specifically the provisions under the section of Managing High Drug costs.	Oppose	$0.00	N/A
Senate Bill	695	An Act to improve the accessibility and affordability of pharmaceutical drugs of public health concern	Oppose	$0.00	N/A
House Bill	966	An Act to promote value-based insurance design in the Commonwealth	Neutral	$0.00	N/A
Executive	Other	Promoted the overall clinical value of prescription medicines and the economic impact of the biotechnology sector in the Commonwealth of MA.	Support	$0.00	N/A
House Bill	969	An Act empowering health care consumers	Support	$0.00	N/A
House Bill	3800	An Act making appropriations for the fiscal year 2020 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements (Amendment #1361)	Oppose	$0.00	N/A
Senate Bill	712	An Act to promote transparency and prevent price gouging of pharmaceutical drug prices	Oppose	$0.00	N/A
House Bill	1186	An Act strengthening HPC and CHIA market oversight	Neutral	$0.00	N/A
House Bill	898	An Act relative to consumer deductibles	Support	$0.00	N/A
Senate Bill	1235	An Act relative to step therapy and patient safety	Support	$0.00	N/A
House Bill	3551	An Act to promote transparency and cost control of pharmaceutical drug prices	Oppose	$0.00	N/A
House Bill	3800	An Act making appropriations for the fiscal year 2020 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements (Amendment 583 to H3800- drug repository program. Amendment #1082 to H3800- Opioid Gross receipts.)	Neutral	$0.00	N/A
Senate Bill	2874	An Act enabling partnerships for growth (specifically supporting the section to extend the prescription drug co-pay assistance program.)	Support	$0.00	N/A
Senate Bill	541	An Act relative to co-pay assistance	Support	$0.00	N/A
House Bill	1167	An Act relative to prescription drug price transparency	Oppose	$0.00	N/A
Senate Bill	1701	An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing	Oppose	$0.00	N/A
House Bill	5164	An Act making appropriations for the fiscal year 2021 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements (Outside section #59 to FY21 Budget which extended the Prescription drug co-pay assistance law for another 2 years through 2023. Amendment #’s 193 & 296- Extension of the Co-Pay Assistance Law. )	Support	$0.00	N/A
Senate Bill	614	An Act to help patients and reduce healthcare costs by ensuring patient adherence to medications	Support	$0.00	N/A
House Bill	1193	An Act providing for the establishment of a drug cost review commission	Oppose	$0.00	N/A
Senate Bill	2984	An Act Promoting a Resilient Health Care System that puts patients first.	Neutral	$0.00	N/A
Executive	Massachusetts Health Policy Commission (HPC)	Direct involvement with the State’s Health Policy Commission (HPC) as a formal member of the Health Policy Commission’s (HPC) Advisory Council in discussions to implement the MA Health Care Cost Containment Law (Chapter 224).	Neutral	$0.00	N/A
House Bill	1853	An Act relative to fail first and patient safety	Support	$0.00	N/A
House Bill	1148	An Act regarding Massachusetts drug price relief	Oppose	$0.00	N/A
Senate Bill	1304	An Act to restore integrity in the marketing of pharmaceutical products and medical devices	Oppose	$0.00	N/A
Senate Bill	733	An Act relative to consumer protection for prescription drug purchases	Neutral	$0.00	N/A
			Total amount	$0.00

Meals, Travel, and Entertainment Expenses

No meals, travel, or entertainment expenses were filed for this disclosure reporting period.

Additional Expenses

Date from	Date to	Recipient name	Expense	Amount
07/22/2020	07/22/2020	Massachusetts Biotechnology Council	Annual meeting fee (virtual).	$850.00
08/18/2020	08/18/2020	Associated Industries of Massachusetts	Associated Industries of MA- Executive Forum (virtual).	$40.00
10/08/2020	10/08/2020	Greater Boston Chamber of Commerce	Government Affairs Forum (virtual).	$25.00
			Total amount	$915.00

Campaign Contributions

Date	Recipient name	Office sought	Amount
07/08/2020	Ted Phillips	State Representative	$200.00
07/22/2020	Joe McGonagle	State Representative	$200.00
09/19/2020	Andy Vargas	State Representative	$200.00
09/28/2020	Tim Whelan	State Representative	$200.00
09/28/2020	Brad Jones	State Representative	$100.00
09/30/2020	Jake Oliviera	State Representative	$100.00
10/19/2020	Jason Lewis	State Senator	$100.00
10/20/2020	Tom Stanley	State Representative	$100.00
10/22/2020	Meg Kilconye	State Representative	$200.00
11/06/2020	Marty Walsh	Mayor of Boston	$200.00
11/20/2020	Joe Wagner	State Representative	$200.00
12/04/2020	Brendan Crighton	State Senator	$100.00
12/14/2020	Charlie Baker	Governor	$200.00
12/15/2020	Aaron Michlewitz	State Representative	$200.00
		Total contributions	$2,300.00

Close this page

Connect with Us